Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
Key facts
- Who runs it
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 21 Nov 2025
- Ended
- 21 Nov 2025
- Type of study
- Interventional
- Treatments tested
- Deucravacitinb
- Record updated
- 24 November 2025
- Why it stopped
- Manufacturer discontinued investigational drug supply.
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (50)Hide the full registry criteria
Who cannot take part
- Prior use of a JAK inhibitor
- Use of other investigational drugs at the time of enrollment
- Concurrent use of any biologic agent other than IVIG
- Change in dose of prednisone within 4 weeks prior to the baseline timepoint
- Prednisone at a dose of 80 mg or more within 4 weeks prior to baseline timepoint
- Intravenous methylprednisolone within 8 weeks prior to baseline timepoint
- Change in dose of methotrexate, azathioprine, mycophenolate, leflunomide, IVIG, cyclosporine, hydroxychloroquine, or tacrolimus within 12 weeks prior to the baseline timepoint
- Patients with other types of myositis or myopathies: polymyositis, paraneoplastic myositis, inclusion body myositis, metabolic or drug induced myopathy, dystrophies
- Recent infection requiring antibiotics in the past 4 weeks before entry of study
- Have had symptomatic herpes zoster infection within 12 weeks prior to entry or during the screening period or recurrent herpes simplex infection
- Have received any live or live attenuated vaccines (including varicella or measles) within 2 months prior to study enrollment
- Have a history of chronic alcohol abuse or intravenous drug abuse within the 2 years prior to entry
- History of previous blood clot such as deep vein thrombosis, pulmonary embolus, or other significant increased risk for blood clots
- Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- History of hypersensitivity to the study drug or drugs of similar chemical classes
- Late-stage DM patients whose muscle weakness, according to the Investigator, could be attributable to muscle damage rather than myositis disease activity
- Patients with history of positive anti-Jo1 or other antisynthetase autoantibodies
- Patients with advanced clinically symptomatic interstitial lung disease
- History of or active rapidly-progressive interstitial lung disease
- History of bowel rupture or inflammatory bowel diseases
- Evidence of latent or active tuberculosis or mycobacterial infections
- History of any malignancy of any organ system (other than localized basal cell carcinoma of the skin or cutaneous squamous cell carcinoma in situ), treated or untreated, within the past 3 years, regardless of whether there is evidence of local recurrence or metastases
- Evidence of any other acute or chronic infectious diseases, including hepatitis, HIV, TB, etc
- Have a history of disseminated/complicated herpes zoster (for example, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, postherpetic neuralgia)
- Current or recent history of uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease
- Any other condition or criterion that, in the judgment of the Investigator, would either pose an unacceptable risk to the participant or interfere with the interpretation of the study results
- Have joint disease or other musculoskeletal condition including contractures or calcinosis, which precludes the ability to quantitate muscle strength
- Total WBC count <2500 cells/microliter; Absolute neutrophil count <= 1000/mm3; platelets <= 100,000/microliter; hemoglobin <= 10gm
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Rituximab use within 6 months
- If rituximab given within 12 months, absence of detectable CD20 cells
- Cyclophosphamide use within 12 months
- Prednisone dose greater than 20 mg/day
- Pregnant or breast-feeding patients
- Adults who lack capacity to consent
- Are unable or unwilling to make themselves available for the duration of the study and/or are unwilling to follow study restrictions/procedures
- Hospitalization within the past 30 days, other than scheduled infusion or procedure
Other criteria
- INCLUSION CRITERIA:; In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male or female, 18 years of age or older, of any race or ethnicity
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Ability to take oral medication and willingness to adhere to the deucravacitinib regimen
- Definite or probable dermatomyositis or juvenile onset dermatomyositis by ACR/EULAR criteria
- Refractory myositis as defined by intolerance or inadequate response to at least a 12-week trial of corticosteroids and at least one other first line immunomodulatory agent. The definition of intolerance is side effect(s) that require discontinuation of the medication or an underlying condition that precludes the further use of the medication. Adequate treatment with corticosteroids or immunomodulatory drugs is defined as at least the lowest of the following doses:; Corticosteroids: 20mg/day for at least 4 weeks with total duration at any dose for at least 12 weeks. If there is intolerance, trial must be for at least 2 weeks; Methotrexate: 15 mg/week for 12 weeks; IVIg: 1 g/kg/month or 60 g/month for 3 months; Azathioprine: 150 mg/d for at least 12 weeks; Mycophenolate mofetil: 1000 mg twice daily for at least 12 weeks; Cyclophosphamide: 500 mg/month intravenously for at least 3 months; Tacrolimus: 5 mg/d for at least 12 weeks; Cyclosporine: 2.4 mg/kg/d for at least 12 weeks; Rituximab: 750mg for at least 2 infusions; Adalimumab: 40mg SQ every other week for at least 12 weeks; Infliximab: 1000mg every 4 weeks for at least 12 weeks; Abatacept:; IV 10mg/kg or 750mg every 4 weeks for 12 weeks; SQ 125mg weekly for at least 12 weeks; Tocilizumab:; ---IV 800mg every 4 weeks for at least 12 weeks; SQ 162mg/dose every 2 weeks for at least 12 weeks; Note: Doses/Timelines may be shorter will still qualify if there is documented intolerance. Other medications can be accepted on a case-by-case basis in consultation with the safety committee
- Concurrent medications: Corticosteroids and non-biologic immunosuppressive/ immunomodulatory drugs can be continued on study. IVIg can also be continued on study. Study participants must be on at least one immunomodulatory medication when enrolling on this study as standard therapy
- Active disease based on Manual Muscle Testing (MMT-8) of <136/150 and any 1 of the following core disease activity measures:; Physician global activity of >= 3.0/10.0; Patient global activity of >= 3.0/10.0; Extramuscular global activity of >= 3.0/10.0; Health Assessment Questionnaire (HAQ) score of >= 0.75
- Women of child-bearing potential must be willing to undergo pregnancy testing at every on-site visit for the duration of the study
- For females of reproductive potential: use of highly effective contraception for at least one month prior to screening and agreement to use such a method during study participation and for an additional 8 weeks after the end of deucravacitinib administration
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
- Must be English-speaking
Where in United States
- National Institutes of Health Clinical CenterBethesda, United States
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Dermatomyositis (DM) and juvenile dermatomyositis (JDM) are diseases that weaken the immune system. DM and JDM can affect the muscles, skin, joints, and lungs and cause skin rashes and muscle inflammation. Symptoms include weakness, pain, fatigue, and rash. Not everyone responds to current treatments. The FDA has approved a drug called deucravacitinib to treat people with plaque psoriasis. Researchers want to find out if this drug can help people with DM or JDM, too.
Objective:
To test deucravacitinib in people with DM or JDM.
Eligibility:
People aged 18 years and older with DM or JDM.
Design:
Participants will have 9 clinic visits over 28 weeks.
Participants will be screened. They will have a physical exam with blood and urine tests. They will have a test of their heart function. They will complete a short questionnaire about their daily life, pain level, and ability to walk, eat, and do other activities.
Deucravacitinib is a pill taken by mouth twice per day at home. Participants will come to the clinic once every 4 weeks for 24 weeks while they are taking the drug. They will have a final visit 4 weeks after their last dose of the study drug. Blood and urine tests will be repeated during these visits. Each visit may take up to 6 hours.
If the drug is helping them, participants may extend their treatment beyond the first 24 weeks. Then they will visit the clinic every 3 months.
The group in the trial
- Drug (Deucravacitinb)Treatment being tested
Participants will receive a 6mg pill taken 2 times per day over 24 weeks and an optional extension period
Treatment: Deucravacitinb
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Open-Label Study of Deucravacitinib for Refractory Adults With Dermatomyositis/ Juvenile Dermatomyositis
- Record updated
- 24 November 2025